BI Sky Global

Innocan Pharma Corporation (OTC:INNPF), an Israel-based cannabinoids-focused pharmaceutical company, reported a 174% year-over-year revenue growth, reaching $24 million for the first nine months of 2024. Quarterly revenues rose 111% YoY to $8.6 million, driven by robust sales from its subsidiary,...

InnoCan Pharma Corp. (OTCQB:INNPF) (CSE:INNO) (FSE: IP4) an Israel-based cannabinoids-focused pharmaceutical company, announced its interim consolidated financial results Monday for the three months ended March 31, 2024. The company reported revenues of $6.8 million, marking a 334% increase...

Innocan Pharma Corporation (OTCQB:INNPF) (CSE:INNO) (FSE: IP4), a cannabinoids-focused pharmaceutical company based in Israel, announced Monday its financial results for the the year ended December 31, 2023. The company reported a nearly sixfold increase in its revenues, reaching US$13.7 million,...

Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) released its audited financial results for the year ended December 31,2022, revealing revenue of $2.6 million, an increase of 1205% from approximately $196,000 in 2021. Financial Highlights for the year ended December 31, 2022 Q4...